Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.
Saved in:
| Title: | Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. |
|---|---|
| Authors: | Clowse MEB; Division of Rheumatology and Immunology, Duke University, Durham, NC, USA. Electronic address: megan.clowse@duke.edu., Isenberg DA; Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, UK., Merrill JT; Oklahoma Medical Research Foundation, Oklahoma City, OK, USA., Dörner T; Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany., Petri M; Johns Hopkins University School of Medicine, Baltimore, MD, USA., Vital EM; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Morand EF; Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, VIC, Australia., Touma Z; Division of Rheumatology, University of Toronto Lupus Clinic, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada., Askanase AD; Columbia University Medical Center, New York, NY, USA., Ioannou Y; UCB, Slough, UK., Brookes S; Biogen, Maidenhead, UK., Gaiha-Rohrbach J; Biogen, Cambridge, MA, USA., Koch ED; UCB, Monheim am Rhein, Germany., Zibian N; UCB, Colombes, France., Martin C; UCB, Slough, UK., Jimenez T; UCB, Raleigh, NC, USA., Nelde A; Biogen, Baar, Switzerland., Stach C; UCB, Monheim am Rhein, Germany. |
| Corporate Authors: | PHOENYCS GO Study Investigators’ Group |
| Source: | Lancet (London, England) [Lancet] 2026 Jun 06; Vol. 407 (10545), pp. 2291-2304. Date of Electronic Publication: 2026 May 29. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
